DBV Technologies S.A.
Montrouge, France, March 1, 2020
DBV Technologies to Report Full Year 2020 Financial Results on March 4, 2021
DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Thursday, March 4, 2021, at 5:00 p.m. ET/23:00 CET to report full year 2020 financial results and provide a corporate update.
This call is accessible via the below teleconferencing numbers, followed by the reference ID: 50114481.
- United States: (866) 866-1333
- Canada: (866)-215-5508
- United Kingdom: 0808 238 9578
- France: 0805 102 604
A live webcast of the call will be available on the Investors & Media section of the Company’s website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBV’s website after the event.
About DBV Technologies
DBV Technologies is developing Viaskin™, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT™, DBV’s method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV’s food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company’s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), and the Company’s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).
Investor Contact
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com
Media Contact
Angela Marcucci
DBV Technologies
+1 646-842-2393
angela.marcucci@dbv-technologies.com
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About Globenewswire
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Sveriges Riksbank8.7.2025 09:30:00 CEST | Press release
CONDITIONS FOR SALE OF RIKSBANK CERTIFICATES
SUSE LLC8.7.2025 09:00:00 CEST | Press release
SUSE Launches European Digital Sovereignty Offering
Heineken8.7.2025 09:00:00 CEST | Press release
New HEINEKEN Study Shows Sports Fans Shifting Gears Toward Moderation
Epiq8.7.2025 09:00:00 CEST | Press release
Epiq Bolsters its Leadership of Class Action Administration in the UK and Europe with the Acquisition of Case Pilots
HEINEKEN International8.7.2025 09:00:00 CEST | Press release
New HEINEKEN Study Shows Sports Fans Shifting Gears Toward Moderation
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom